Chronic inflammatory demyelinating polyneuropathy during treatment with interferon-alpha

Exacerbation of Chronic Inflammatory Demyelinating Polyradiculoneuropathy during Interferon.BETA.-1b Therapy in a Patient with Childhood-onset Multiple Sclerosis

“…It was considered that IFN treatment somehow contributed to the development of CIDP. This hypothesis is supported by recent reports documenting the onset of CIDP in patients receiving type I IFN (8)(9)(10). Here, we report a female patient who developed MS in childhood and underwent interferon -1b treatment in early adult life, which caused CIDP that was successfully treated by oral corticosteroids.…”

Chronic Inflammatory Demyelinating Polyneuropathy Due to the Administration of Pegylated Interferon .ALPHA.-2b: A Neuropathology Case Report

“…On the other hand, however, a favorable outcome was reported in all of the reported cases of IFNα-induced CIDP when the patients were treated with any of the standard therapies for CIDP, including oral steroids (6,8), plasma exchange (7,11), or IVIG (8)(9)(10)12). In the present case, three courses of IVIG were administered, but no maintenance immunomodulatory therapy was needed.…”

“…On the other hand, autoimmunity is a well-recognized complication of IFNα therapy, with reported frequencies ranging between 4.3% and 18.5% in large observational studies (3)(4)(5). Neuropathies due to administration of IFNα are a rare complication (3,4); however, eight distinct case reports have shown that chronic inflammatory demyelinating polyneuropathy (CIDP) can result from administration of IFNα, presumably due to perturbations in the host immune system (6)(7)(8)(9)(10)(11)(12)(13). We here report a biopsy-proven case with IFNα-induced CIDP in which the serum value of tumor necrosis factor-α (TNFα) was elevated.…”

Polineuropatia desmielinizante inflamatória crônica pós-tratamento com interferon peguilado alfa 2b em um paciente co-infectado HIV/HCV: relato de caso

“…Apesar de ser uma reação adversa pouco comum, outros casos na literatura vem demonstrando essa associação 2,3,7,10 , e o fato da estavudina poder ter concorrido para este quadro representa mais um alerta aos médicos que tratam pacientes co-infectados HIV/HCV, para as possíveis toxicidades concomitantes das medicações usadas.…”